Intercept Pharmaceuticals Receives FDA Orphan Drug Designati

Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)

Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Austria , United States , Vienna , Wien , Nareg Sagherian , Karen Preble , M Michelle Berrey , Drug Administration , Nasdaq , Global Corporate Communications , Intercept Pharmaceuticals Inc , European Association For The Study , Linkedin , Office Of Orphan Drug Products , Research Development , Company On Twitter , Chief Medical Officer , European Association , Orphan Drug Products , Bezafibrate Fixed Dose Combinationintercept , Primary Biliary Cholangitisprimary , Looking Statementsthis , Executive Director , Global Investor , Global Corporate , Intercept Pharmaceuticals ,